This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s […]
Natural Products – Part 3: Ensuring Patentability for Novel Diagnostics and Therapies Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Legal and regulatory update
Go to paperABSTRACT: Article 81(1) of the Treaty of Rome prohibits all agreements, decisions and concerted practices that ma…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Growth of Indian biotech companies, in the context of the international biotechnology industry
Go to paperABSTRACT: The paper discusses the evolution and…
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patent issues and future trends in drug development
Go to paperABSTRACT: The global biopharmaceutical industry has been one of the most productive and p…
Patent issues and future trends in drug development Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Natural Products – Part 2: From the Biomes to the Microbiome Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Natural Products: A New Golden Age in Drug Development? Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ApaTech: A biomaterials success story
Go to paperABSTRACT: ApaTech is an excellent example of how innovative technology from a British university can be…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ABSTRACT:
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website
Why data exclusivity is the new patent protection Read Post »
The article proposes a “virtual” biotech model for the emerging markets – termed EmergingCo – and develops a comparative financial model to argue that such a virtual biotech can deliver drug candidates from discovery through proof-of-concept (Phase II) more cost effectively than the traditional drug development paradigm. Data from published studies on drug development costs have been compared with a cost structure model for EmergingCo using a framework where all R&D can be accomplished through a virtual network of partnerships within emerging markets. A couple of case studies from China and India are used to lend support to the cost structure model. Such a model, either as a venture backed company or a virtual unit of big pharma, could provide an alternate vehicle for delivering mid-to late stage clinical candidates, similar to Lilly’s Chorus model.
EmergingCo: A Virtual “South-South” Biotech Model Read Post »